Institutional flow

Institutional Flow — Scan of Aug 22, 2026

Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.

Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
5funds adding
4new positions
$6.16Bheld by those funds

AIThis scan

Five names surfaced from the Q2 2026 (period 2026-06-30) vs Q1 2026 (period 2026-03-31) 13F comparison across Berkshire Hathaway, Bridgewater, Renaissance Technologies, Citadel Advisors, and Two Sigma. Of 871 tickers that technically passed the acceleration filter across the five funds, only a handful combined multi-manager conviction with genuine retail invisibility. The single most notable finding: Berkshire added 17.5 million shares of Delta Air Lines (+44%), materially extending an airline stake Buffett famously eliminated in April 2020 — a philosophical about-face on the sector that retail is still treating as un-investable.\n\nThe remaining four picks — NiSource, Ensign Group, Churchill Downs, and FormFactor — were each accumulated by all four non-Berkshire managers in the watchlist, with Bridgewater or Renaissance opening fresh positions in three of the four. These are quiet, business-quality names sitting outside the AI/mega-cap headline cycle, where quant + macro managers appear to be leaning on structural cash flows (utility rate base, skilled-nursing rollup, gaming HHR, HBM test intensity) that haven't shown up in retail chatter.

How this scan was run

Compared the two most recent 13F-HR filings for each of the five configured funds (Berkshire, Bridgewater, RenTech, Citadel, Two Sigma) — all filed Aug 13-14, 2026 for period 2026-06-30 vs. May 14-15, 2026 for period 2026-03-31 — via fetch_13f_holdings. Aggregated shares by CUSIP within each fund, then computed per-CUSIP acceleration across all five managers. Qualification required net buyers > net sellers AND (aggregate share count +25% Q/Q OR ≥2 new positions), with a single-fund concentration cap of 80% of the aggregate delta (Berkshire exempt — block buys are the signal). Puts were excluded (hedges); calls counted. Mega-cap retail favorites (Alphabet ranked #3 and #6 in raw output) were removed per rails, along with sub-$1B and sub-$10M-ADV names, and any candidate reporting earnings within 7 trading days. Slower-moving managers (Berkshire, Bridgewater) were weighted higher in thesis-writing than pure quant flow. All five funds returned holdings cleanly; no fund failures. Google Trends and news-count estimates below are conservative directional reads, not full-sample retrievals (30-day counts were spot-checked via web search rather than a formal aggregator run).

#1

DAL

Delta Air Lines, Inc.
IndustrialsMkt cap $53.6BNext earnings Oct 10, 2026
Price
$82.41
Est. fund entry
$93.65-12.0%
Shares held
57.4M
Position value
$5.37B
Funds that added
FundPrior sharesShares nowChange
Berkshire Hathaway39.8M57.3M+44.0%
Two Sigma Investments—22.2KNew position
Bridgewater Associates22.1K22.4K+1.1%
Retail attention 3 of 4 signals quiet
Google Trends22/100quiet
News, 30 days18 articlesbusy
Call/put OI1.60quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Berkshire eliminated all four US airline holdings in April 2020 and Buffett publicly labeled it a mistake to have owned them. Re-adding 17.5 million DAL shares this quarter — a +44% escalation on top of the existing 39.8 million share position — is a material philosophical reversal, not a marginal rebalance. Delta is the airline with the strongest premium-cabin monetization and the Amex co-brand cash-flow annuity, which reads as the Buffett-style moat that would justify the return. Retail still treats US legacy carriers as un-investable post-COVID; the catalyst institutions likely see is a resilient corporate-travel setup into the 2026 holiday schedule against a stock that has actually fallen ~12% from the Q2 mark.

What would prove it wrong

If Buffett/Abel are wrong on corporate travel elasticity, DAL earnings compress fast — airlines have operational leverage in both directions. Fuel price shocks and any macro deceleration hit legacy carriers first. Citadel actually trimmed DAL ~30% this quarter, so the signal is not unanimous.

#2

NI

NiSource Inc.
UtilitiesMkt cap $18.3BNext earnings Nov 4, 2026
Price
$40.62
Est. fund entry
$47.61-14.7%
Shares held
6.07M
Position value
$289.0M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors854.3K3.83M+348.0%
Bridgewater Associates—1.41MNew position
Renaissance Technologies9.00K747.3K+8203.3%
Two Sigma Investments62.7K85.3K+36.0%
Retail attention 3 of 3 signals quiet
Google Trends9/100quiet
News, 30 days7 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

NiSource is a regulated natural gas and electric utility across Indiana, Ohio, Pennsylvania, Virginia, Kentucky, and Maryland — geography that sits directly under the Midwest AI data-center buildout. Four of four non-Berkshire funds accumulated, including Bridgewater opening a fresh 1.41 million share position — Bridgewater new positions in single-name utilities are rare and typically reflect a macro thesis on regulated rate-base growth. Renaissance's 8,000% Q/Q increase suggests factor models are catching the same rate-case tailwind. Catalyst institutions likely see: pending Indiana and Virginia data-center-driven rate cases that lift the earned-return base into 2027, a signal retail hasn't priced because 'utility' still reads as low-beta ballast rather than the AI power trade.

What would prove it wrong

Utility performance depends on regulator cooperation — an unfavorable Indiana Utility Regulatory Commission ruling would cut the thesis. Rate-shock politics could compress allowed ROEs. And the stock has already fallen ~15% from the Q2 mark, so smart money isn't visibly right yet.

#3

ENSG

The Ensign Group, Inc.
Health CareMkt cap $10.2BNext earnings Oct 22, 2026
Price
$179.48
Est. fund entry
$160.44+11.9%
Shares held
374.0K
Position value
$60.0M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors33.8K169.6K+402.5%
Two Sigma Investments13.5K156.7K+1058.1%
Renaissance Technologies21.4K35.3K+65.0%
Bridgewater Associates6.34K12.3K+94.3%
Retail attention 3 of 3 signals quiet
Google Trends8/100quiet
News, 30 days5 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Ensign operates 300+ skilled-nursing and post-acute facilities and has compounded book value ~15% annually via disciplined single-facility acquisitions. All four non-Berkshire managers accumulated — Two Sigma up 1,058%, Citadel up 403% — suggesting quant models are catching the same operational quality signal. Skilled nursing carries residual retail stigma from COVID; that mispricing is the edge. Catalyst institutions likely see: 2027 Medicare skilled-nursing rate updates that were more favorable than the market priced, plus the Ensign playbook's continued sub-scale-operator rollup accretion in Texas and the Southeast.

What would prove it wrong

Medicare/Medicaid reimbursement is exogenous and one adverse CMS rule can compress margins across the entire portfolio. Labor-cost inflation in nursing has been the single biggest sector headwind. Stock is already up ~12% from the Q2 mark so institutions are visibly ahead — the easy money may already be in.

#4

CHDN

Churchill Downs Incorporated
Consumer DiscretionaryMkt cap $6.7BNext earnings Oct 28, 2026
Price
$93.71
Est. fund entry
$89.30+4.9%
Shares held
2.50M
Position value
$223.0M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors1.29M1.74M+35.1%
Two Sigma Investments258.8K572.3K+121.2%
Renaissance Technologies—165.2KNew position
Bridgewater Associates4.14K14.1K+241.0%
Retail attention 3 of 3 signals quiet
Google Trends18/100quiet
News, 30 days11 articlesquiet
Call/put OI—n/a
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

Retail understands Churchill Downs as 'the Kentucky Derby company' — a single spring event. Institutions understand it as a portfolio of historical-horse-racing (HHR) gaming machines in Kentucky and Virginia plus regional casinos, where recurring machine revenue now drives the majority of EBITDA. Renaissance opening a fresh 165K-share position while Two Sigma added 121% is unusual quant + quant conviction on the same discretionary name. Catalyst: continued Virginia HHR facility ramp and the Terre Haute, Indiana casino opening cycle, both of which show up in EBITDA before they show up in the sell-side headlines retail reads.

What would prove it wrong

Gaming regulation shifts (particularly HHR legality in states that could revisit it) are the biggest overhang. Consumer discretionary spend rolling over would compress regional casino visitation. Insider selling into strength has been a recurring pattern for this name.

#5

FORM

FormFactor, Inc.
Information TechnologyMkt cap $8.8BNext earnings Oct 28, 2026
Price
$114.16
Est. fund entry
$159.66-28.5%
Shares held
1.37M
Position value
$218.0M
Funds that added
FundPrior sharesShares nowChange
Citadel Advisors255.7K481.6K+88.4%
Two Sigma Investments213.5K425.7K+99.4%
Renaissance Technologies—295.6KNew position
Bridgewater Associates50.2K162.6K+223.8%
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days9 articlesquiet
Call/put OI1.20quiet
Retail hotlistsNot listedquiet

AIWhy these funds may be buying

FormFactor is the pure-play probe card and semiconductor test manufacturer — the picks-and-shovels exposure to HBM test intensity and advanced-node logic. All four non-Berkshire funds added while the stock fell roughly 28% from the Q2 mark; classic institutional buying-weakness signature. Renaissance opened a fresh 295K-share position, which suggests factor models are catching the HBM4 ramp cycle that hasn't yet shown up in FORM's reported revenue mix. Catalyst institutions likely see: HBM4 volume production ramping in H2 2026, plus advanced-packaging test intensity per die stepping up with 2nm logic, both of which flow into probe-card ASP and consumables revenue before retail notices.

What would prove it wrong

Probe card demand is a derivative of memory and foundry capex — an AI capex pause would hit FORM disproportionately hard because most of its revenue is late-cycle within the semi supply chain. The stock's 28% drawdown from the Q2 institutional mark says the market disagrees with the thesis right now. Customer concentration in memory (SK Hynix, Samsung, Micron) is another concentrated risk.

All scans

Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones — while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartCreate a free account

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.